Clinical Trials in Dallas

Showing 4581-4600 of 17,468 trials

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

NCT03471117

Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.

Chronic Kidney Diseases

The University of Texas at Arlington28 participantsStarted Apr 2018

Arlington, Texas, United States • Dallas, Texas, United States

Active Not RecruitingPhase 3< 1 mile

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

CoughRefractory Chronic Cough

Bellus Health Inc. - a GSK company825 participantsStarted Oct 2022

Litchfield Park, Arizona, United States • Scottsdale, Arizona, United States • Encinitas, California, United States +188 more locations

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Find Trials by Condition in Dallas

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)

Alzheimer's Plasma Extension

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Promoting Shared Decision Making for Severe Aortic Stenosis

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

ProVIDE II Bridging Study

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

Medical Access Program for Patritumab Deruxtecan

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Validation of a Multi-gene Test for Lung Cancer Risk

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects